• 477
  • 55
  • Favorite

Britain approves Pfizer-BioNTech shot for younger children

Reuters2021-12-22

LONDON, Dec 22 (Reuters) - Britain's medicines regulator on Wednesday approved use of the COVID-19 vaccine from partners Pfizer and BioNTech for children aged 5 to 11 years, after the watchdog found the shot was safe and effective.

The country's vaccines committee advised that children in the age group who were in a clinical risk group should be offered the shot.

The children will receive two 10-microgram doses of the Pfizer-BioNTech vaccine - a third of the adult dose - with an interval of eight weeks between the first and second doses, the Joint Committee on Vaccination and Immunisation said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment55

  • gil dina
    ·2021-12-23
    Like
    Reply
    Report
  • hktiigeracct
    ·2021-12-23
    Noted
    Reply
    Report
  • sheyx
    ·2021-12-23
    Good
    Reply
    Report
  • Gackky
    ·2021-12-23
    BNTX lets fly[LOL] 
    Reply
    Report
  • yonglh
    ·2021-12-23
    Like pls 
    Reply
    Report
  • WJ77
    ·2021-12-23
    👍👍
    Reply
    Report
  • Sorrie2u
    ·2021-12-23
    Good
    Reply
    Report
  • PearlynCSY
    ·2021-12-23
    SINGAPORE: The Ministry of Education (MOE) and Early Childhood Development Agency announced the beginning of the COVID-19 vaccination programme for children aged five to 11 on Tuesday (Dec 21).Singapore approved the Pfizer-BioNTech/Comirnaty COVID-19 vaccine for use in children in this age group earlier this month. And vaccinations will begin as planned with the expected arrival of the first shipment of paediatric vaccine doses on Wednesday, the Ministry of Health (MOH) said.  MOE and ECDA said that the Phase 3 clinical trial of the vaccine has shown that the Pfizer BioNTech/Comirnaty COVID-19 vaccine is safe and effective for children in this age group.The Expert Committee on COVID-19 Vaccination has assessed that the “benefits of vaccination far outweigh the risks”, the agencies add
    Reply
    Report
    Fold Replies
    • PearlynCSY
      Tks for sharing
      2021-12-24
      Reply
      Report
    • cheeryk
      This means that the epidemic has been effectively controlled in Singapore. Praise Pfizer-BioNTech/Comirnaty
      2021-12-23
      Reply
      Report
    • blinkix
      Can the global economy fully recover in 2022? Let's end the epidemic quickly.
      2021-12-23
      Reply
      Report
    View more 2 comments
  • Sunshine8888
    ·2021-12-23
    Oy
    Reply
    Report
    Fold Replies
    • Sorrie2u
      ok
      2021-12-23
      Reply
      Report
  • Slee49
    ·2021-12-23
    Good
    Reply
    Report
    Fold Replies
  • k1wong
    ·2021-12-23
    K
    Reply
    Report
  • fysx49
    ·2021-12-23
    Prepare for endemic stage
    Reply
    Report
  • Renzo Piano
    ·2021-12-23
    [Claw] 
    Reply
    Report
  • ALLOYHUAT
    ·2021-12-23
    Like
    Reply
    Report
  • 陈河马
    ·2021-12-23
    Wow
    Reply
    Report
    Fold Replies
  • Norico
    ·2021-12-23
    Great news
    Reply
    Report
  • keithwb
    ·2021-12-23
    Loyalty card for kids coming soon~
    Reply
    Report
  • ggwei
    ·2021-12-23
    About time.. 
    Reply
    Report
  • keanuchin
    ·2021-12-23
    Good.
    Reply
    Report
  • saket
    ·2021-12-23
    Cool
    Reply
    Report
 
 
 
 

Most Discussed

 
 
 
 
 

7x24

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial